CurrentCapital BluecrossPolicy MP 1.084

Radiofrequency Ablation of Miscellaneous Solid Tumors (excluding liver)

Customize your policy alerts

Sign up for Capital Bluecross Policy MP 1.084 alerts

Get alerted when Policy MP 1.084 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs medical necessity and coverage criteria for radiofrequency ablation (RFA) of non-liver solid tumors (e.g., bone, kidney, lung, breast, and other miscellaneous tumors) and applies to Capital BlueCross-administered products with noted product variations.

Policy Summary

PayerCapital Bluecross

PolicyRadiofrequency Ablation of Miscellaneous Solid Tumors (excluding liver)

Policy CodePolicy MP 1.084

Change TypeNo material clinical or coverage changes

Effective DateMay 1, 2026

Last ReviewOct 22, 2025

Next Review Date

Key ActionObtain prior authorization and document tumor size, location relative to adjacent critical structures, prior treatments, and why standard therapies failed or are unsuitable.

SourceLink

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentCapital BluecrossPolicy MP 1.084

Radiofrequency Ablation of Miscellaneous Solid Tumors (excluding liver)

Customize your policy alerts

Sign up for Capital Bluecross Policy MP 1.084 alerts

Get alerted when Policy MP 1.084 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerCapital Bluecross

PolicyRadiofrequency Ablation of Miscellaneous Solid Tumors (excluding liver)

Policy CodePolicy MP 1.084

Change TypeNo material clinical or coverage changes

Effective DateMay 1, 2026

Last ReviewOct 22, 2025

Next Review Date

Key ActionObtain prior authorization and document tumor size, location relative to adjacent critical structures, prior treatments, and why standard therapies failed or are unsuitable.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≤ 4 cmrenal tumor max size

≤ 3 cmlung lesion max size

1 cmminimum lung distance

≤ 3max tumors per lung

12 morepeat lung ablation interval

insufficientbreast RFA evidence

Coverage Criteria — Indications and Evidence

Painful osteolytic bone metastases (palliative)

Covered when ALL of the following are met:

Bone metastases RFA criteria: Patient has painful osteolytic bone metastases

AND the patient has failed or is a poor candidate for standard treatments such as radiation or opioids (RFA may be considered medically necessary for palliation)

Osteoid osteoma

Covered when ALL of the following are met:

Osteoid osteoma criteria: Osteoid osteoma that cannot be managed successfully with medical treatment

RFA may be considered medically necessary

Localized renal cell carcinoma (RCC)

Covered when ALL of the following are met:

Localized RCC criteria: Tumor is localized renal cell carcinoma no more than 4 cm in size<= 4 cm

AND either: to preserve kidney function in patients with significantly impaired renal function (one kidney or GFR <60 mL/min/m^2) when standard surgical resection is likely to substantially worsen kidney function, OR the patient is not a surgical candidate; RFA may be considered medically necessary in these circumstances.

Isolated peripheral non-small cell lung cancer (primary) or malignant nonpulmonary tumors metastatic to lung

Covered when ALL of the following are met:

Lung primary or metastatic tumor criteria: Lesion is an isolated peripheral non-small cell lung cancer ≤3 cm OR malignant nonpulmonary tumor metastatic to the lung ≤3 cm<= 3 cm; distance >= 1 cm

AND surgical resection or radiation with curative intent is appropriate based on stage but the patient is unfit due to medical co-morbidity OR the patient is not a surgical candidate; AND the tumor is located at least 1 cm from the trachea, main bronchi, esophagus, aorta/aortic branches, pulmonary artery and heart; AND for metastatic lung tumors, there is no evidence of extrapulmonary metastases when ablation is proposed; Additional guidance: no more than 3 tumors per lung should be ablated; tumors should be amenable to complete ablation; wait 12 months before repeat ablation.

Evidence-based coverage statements by tumor type

Policy summary statements about clinical evidence and coverage implications for specific tumor groups

Breast tumors: Evidence includes observational studies and systematic reviews reporting varied and incomplete ablation rates and concerns about post-ablation tumor cell viability; long-term improvements in health outcomes have not been demonstrated and comparisons with conventional breast-conserving procedures are not available.

Evidence is insufficient to determine effects on health outcomes.

Miscellaneous solid tumors (e.g., head and neck, thyroid, pancreas): Evidence consists of a few case series, prospective and retrospective studies with limited reporting and limited comparisons; reporting does not permit conclusions on health benefits of RFA for these tumor types.

Evidence is insufficient to determine impact on health outcomes.

This policy addresses radiofrequency ablation (RFA) of non-liver solid tumors and defines specific indications that may be considered medically necessary versus those considered investigational. RFA may be considered medically necessary for certain indications when ALL specified criteria are met (see individual criteria groups). Relevant, tumor-specific thresholds in this policy include renal tumors ≤ 4 cm for localized renal cell carcinoma and isolated peripheral non-small cell lung cancer or malignant nonpulmonary metastatic lung tumors ≤ 3 cm with the tumor located at least 1 cm from major thoracic/mediastinal structures. The policy title explicitly excludes liver tumors ("EXCLUDING LIVER TUMORS").

RFA is considered investigational and therefore not covered for multiple other indications including: breast tumors; lung tumors that do not meet the lung-specific criteria above; renal tumors that exceed the renal size/location criteria or do not meet the renal-specific criteria; osteoid osteomas that can be managed with medical therapy; use of RFA as the initial treatment for painful bony metastases; and other non-liver tumors outside the listed medically necessary indications (for example head and neck, adrenal gland, ovary, and unspecified pelvic/abdominal metastases). There is insufficient evidence to support general conclusions about health outcomes for these investigational indications.

Procedures designated "Investigational; therefore, not covered" are excluded from coverage when billed under the procedure codes listed in the coding section. Providers should note that submission of an excluded procedure code identified as investigational may result in claim denial.

The policy title and scope expressly exclude management of hepatic tumors; this document governs RFA of miscellaneous solid tumors excluding liver tumors. For RFA of primary or metastatic liver tumors, refer to the separate policy MP 1.055.

For indications listed as investigational, the evidence is limited and does not permit general conclusions about improvements in health outcomes. Specifically, studies for these uses are primarily observational, case series, or small comparative studies with limited reporting and follow-up; therefore these indications are considered investigational due to insufficient evidence to demonstrate meaningful long-term patient benefit.

Examples of insufficient evidence include RFA for breast tumors, where observational studies and systematic reviews report variable and incomplete ablation rates, concerns about post-ablation tumor cell viability, and no demonstrated long-term outcome improvements compared with conventional breast-conserving procedures. Similarly, miscellaneous solid tumors (e.g., head and neck, thyroid, pancreas) have a limited evidence base with sparse outcome reporting, preventing conclusions about clinical benefit.

Specifically for breast tumors, available evidence consists of observational studies and systematic reviews showing variable and incomplete ablation and concerns about residual viable tumor cells after RFA; long-term improvements in disease control, survival, or other health outcomes have not been demonstrated. As a result, RFA for breast tumors is considered investigational pending higher-quality studies with long-term follow-up that compare RFA with standard breast-conserving treatments.

Policy positions for particular indications have changed over time as evidence and guideline recommendations evolved. The policy history documents instances where indications (for example, thyroid tumor indications and specific CPT codes) were moved between medically necessary and investigational categories; therefore, an indication listed as medically necessary in one policy version may later be reclassified as investigational (or vice versa) based on updated evidence and policy decisions.

Coding — CPT, ICD-10, and Code Status

Investigational; therefore, not coveredCPTNot Covered

41530

Procedure code listed under Investigational; therefore, not covered (as presented in document)

Covered when medically necessaryCPTCovered

20982	Procedure code listed as Covered when medically necessary
32998	Procedure code listed as Covered when medically necessary
50542	Procedure code listed as Covered when medically necessary
50592	Procedure code listed as Covered when medically necessary

ICD-10-CM Diagnosis Codes (as listed)ICD-10

C34.01	ICD-10-CM diagnosis code listed in policy
C34.02	ICD-10-CM diagnosis code listed in policy
C34.11	ICD-10-CM diagnosis code listed in policy
C34.12	ICD-10-CM diagnosis code listed in policy
C34.2	ICD-10-CM diagnosis code listed in policy
C34.31	ICD-10-CM diagnosis code listed in policy
C34.32	ICD-10-CM diagnosis code listed in policy
C64.1	ICD-10-CM diagnosis code listed in policy
C64.2	ICD-10-CM diagnosis code listed in policy
C73	ICD-10-CM diagnosis code listed in policy

1–10 of 24

1/3

Policy-related CPT code historyCPT

50542	Code added as medically necessary (per policy history)
0404T	Code removed from investigational (per policy history)
60660	Code added then later moved/removed from policy (per policy history)
60661	Code added then later moved/removed from policy (per policy history)

Localized renal tumor size — key value (≤ 4 cm)

ThresholdLocalized renal tumor size must be ≤ 4 cm

Clinical contextIndication: localized renal cell carcinoma when ablation preserves kidney function in patients with one kidney or GFR <60 mL/min/m^2 or when patient is not a surgical candidate

Coverage implicationTumors >4 cm do not meet the medically necessary size criterion and risk denial as investigational

Lung lesion size — key value (≤ 3 cm)

ThresholdLung lesion (primary or metastatic) must be ≤ 3 cm

Distance requirement

Provider Actions — Authorization, Documentation, and Denial Risks

Prior Authorization

Obtain prior authorization for eligible RFA

Prior authorization is required for RFA under this policy for applicable Capital Blue Cross products; requesters must demonstrate that coverage criteria (e.g., tumor size, location/distance requirements, and that standard therapies have failed or the patient is a poor surgical candidate) are met.

Policy applies only to certain Capital Blue Cross programs and products (see Product Variations).
Authorization should document how the case meets size, location, and prior-therapy criteria in the Coverage Criteria.

Prior Authorization

Request prior authorization and medical review for listed CPT codes

Procedure codes listed as “Covered when medically necessary” require prior medical review and coverage determination based on member benefit information and medical necessity.

Examples of listed covered procedure codes: 20982, 32998, 50542, 50592.
Identification of a code in the policy does not by itself guarantee coverage; authorization and benefit verification are required.

Background — Technique and Clinical Context

Radiofrequency ablation (RFA) is a thermal coagulation technique that uses alternating current delivered through probe electrodes to produce coagulative necrosis of targeted soft tissue or tumors. It was initially developed for liver tumors and may be performed via percutaneous, laparoscopic, or open surgical approaches with image guidance. Intended goals include local tumor control and symptom palliation, with effectiveness depending on delivered energy, tissue characteristics, and probe design; potential complications include thermal injury to adjacent structures and procedure-related risks such as pneumothorax when traversing the lung.

Definitions and Key Terms

Radiofrequency ablation (RFA) — definition and device clearance context

DefinitionRadiofrequency ablation (RFA) is a thermal coagulation necrosis technique using alternating current to ablate soft tissue and tumors

Delivery approachesRFA can be performed percutaneously, laparoscopically, or via open surgery with ultrasound or CT guidance

Regulatory/device contextFDA has cleared RFA devices for general soft tissue cutting, coagulation, and thermal ablation; some devices cleared for liver lesions and bone palliation but none cleared specifically for lung tumor ablation

ADJUVANT — definition

DefinitionAdjuvant: a substance, especially a drug, added to a prescription to assist in the action of the main ingredient

Usage context

Policy Revision History and References

2026-05-01Policy effective dateLatest

Policy effective date recorded as 2026-05-01 for MP 1.084 (Radiofrequency ablation of miscellaneous solid tumors, excluding liver).

2025-10-22Last review

Last clinical review of the policy documented on 2025-10-22 (policy statements and references reviewed).

2025-01-01Code update

Policy Summary

PayerCapital Bluecross

PolicyRadiofrequency Ablation of Miscellaneous Solid Tumors (excluding liver)

Policy CodePolicy MP 1.084

Change TypeNo material clinical or coverage changes

Effective DateMay 1, 2026

Last ReviewOct 22, 2025

Next Review Date

Key ActionObtain prior authorization and document tumor size, location relative to adjacent critical structures, prior treatments, and why standard therapies failed or are unsuitable.

SourceLink

On This Page

Tumor must be located ≥ 1 cm from trachea, main bronchi, esophagus, aorta/aortic branches, pulmonary artery and heart

Additional lung constraintsNo evidence of extrapulmonary metastases for metastatic tumors; no more than 3 tumors per lung should be ablated

None specified — placeholder key/value from coding section

SpecificationNone specified (no threshold/value listed in coding thresholds)

ContextListed under coding thresholds as an empty/unspecified entry

Coverage noteAbsence of a specified threshold may require reliance on other policy criteria and clinical documentation

Billing Rule

Verify current CPT code coverage before submission

Monitor policy history and coding updates: CPT codes have been added, moved, or removed over time which can change coverage status; confirm current policy coding before submission.

Policy history documents adding 50542 as medically necessary and later code movements (e.g., 60660/60661 were added then removed).
Verify the active coverage status of codes before billing or requesting authorization.

Step Therapy

Ensure step requirement is met for bone metastases

For painful osteolytic bone metastases, RFA is indicated only after failure of or if the patient is a poor candidate for standard treatments (for example, radiation or opioids); document prior treatment failure or contraindication.

Policy: “Radiofrequency ablation may be considered medically necessary to palliate pain in patients with osteolytic bone metastases who have failed or are poor candidates for standard treatments such as radiation or opioids.”

Note

Provider action (see full policy if applicable)

(Reserved) No explicit additional action text provided in the excerpt; retain for reference to full policy if needed.

Note

Provider note — consult policy history

(Reserved) Unspecified provider note retained for historical/contextual references; consult full policy history for details on past code/coverage changes.

Documentation Required

Provide required clinical documentation with authorization request

Include clinical documentation showing tumor size, exact anatomic location and distance from critical thoracic/mediastinal structures (e.g., ≥1 cm for lung lesions), prior treatments and why standard therapies failed or are inappropriate, the number of pulmonary tumors proposed for ablation, and rationale for procedural candidacy.

Document tumor dimensions (renal ≤4 cm; lung/metastatic lung ≤3 cm) and distance from trachea, main bronchi, esophagus, aorta/aortic branches, pulmonary artery, and heart.
For lung: document number of tumors per lung (policy: no more than 3) and intent to allow complete ablation.

Billing Rule

Coding does not equal coverage — verify benefits and medical necessity

The presence of a CPT code in the policy does not imply automatic coverage; coverage decisions rely on member benefit terms and demonstrated medical necessity.

“The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information.”

Documentation Required

Consult full policy for any additional authorization documentation requirements

(Fallback) The excerpt does not list additional explicit authorization documentation fields; consult the full policy or prior authorization instructions for any supplemental required forms or imaging requirements.

Policy excerpts contain title, references, and history but do not enumerate all authorization form requirements; obtain full policy/UM instructions when preparing requests.

Denial Risk

Denial risk when size or location criteria are not met

RFA procedures that exceed stated size limits or fail to meet location/distancing criteria risk denial as investigational or not medically necessary.

Renal tumors >4 cm and lung lesions or metastatic lung tumors >3 cm are outside the covered size limits.
Lung lesions must be located at least 1 cm from the trachea, main bronchi, esophagus, aorta/aortic branches, pulmonary artery and heart; failure to meet this may lead to denial.

Denial Risk

Risk of denial for investigational procedures/indications

Procedures specifically designated in the policy as “Investigational; therefore, not covered” (e.g., listed investigational CPT codes and investigational indications such as breast tumors or lung tumors not meeting criteria) may be denied when billed.

Policy identifies investigational procedure codes (Investigational; therefore, not covered) and lists investigational indications including breast tumors and other uses.
Claims for investigational indications or investigational-coded services are subject to denial.
See Coding section for codes listed as investigational.

Note

Check policy history for CPT code status changes

(Reserved) Policy history notes movement of CPT codes between investigational and medically necessary categories; consult the full history when coding or appealing coverage decisions.

Recent history: removed code 0404T from investigational and added 50542 as medically necessary; codes 60660/60661 were added then later removed.
Code movements can change adjudication — verify active policy status.

Commonly used in oncology to enhance the effect of primary therapy

Policy originDefined in policy's Definitions section

ALKYLATING AGENT — definition

DefinitionAlkylating agent: any substance containing an alkyl radical capable of replacing a free hydrogen atom in an organic compound, interfering with mitosis and cell division

Clinical roleUsed in cancer treatment to disrupt proliferating tissue

Policy originDefined in policy's Definitions section

Radiofrequency ablation of miscellaneous solid tumors (excluding liver) — term/phrase definition

TermRadiofrequency ablation of miscellaneous solid tumors (excluding liver): the procedural category in this policy addressing RFA for non-liver tumors (e.g., bone, kidney, lung, breast, and other miscellaneous tumors)

Policy scopePolicy title explicitly excludes liver tumors from this policy; liver RFA addressed in a separate policy (MP 1.055)

Evidence noteClinical evidence varies by tumor type; some indications are considered investigational due to insufficient evidence

CPT codes 60660 and 60661 were added to the policy effective 01/01/2025 and later moved/removed in subsequent history entries.

2020-08-06Consensus review

Consensus review on 08/06/2020 with references updated; policy statements noted as unchanged at that time per policy history.